Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

NCT05266456 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

835

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Vaccines

Interventions

BIOLOGICAL: 24 valent pneumococcal conjugate vaccine
BIOLOGICAL: 20 valent pneumococcal conjugate vaccine

Sponsor

Vaxcyte, Inc.